UPDATE: BMO Capital Markets Reiterates Outperform Rating on CareFusion Citing Adherence to Corporate Strategy

In a report published Friday, BMO Capital Markets analyst Joanne K. Wuensch reiterated an Outperform rating on CareFusion

and raised the price target to $41 from $38. In the report, BMO Capital Markets noted, "We reiterate our Outperform rating on shares of CFN. The stock has run hot and heavy YTD, rising 31.5% versus the S&P 500's 14.4%. Some of the ascent, we believe, is associated with continued execution of the company's strategic plan, particularly operating margin expansion and anticipation that the company will expand its footprint through acquisition (which we expect, although management appears to be sensitive to the strategic fit and price)". CareFusion closed on Friday at $37.55.